Two assumptions come up constantly in conversations about blood pressure: that feeling fine means your numbers are fine, and that there's one correct target everyone should be hitting. Neither holds up against how blood pressure is actually studied and managed. This page walks through what the evidence shows on both questions, and what it doesn't settle for you individually.
Myth: If You Feel Well, Your Blood Pressure Is Normal
This is false for the large majority of people with elevated blood pressure. Hypertension is frequently described in clinical literature as a “silent” condition precisely because it rarely produces noticeable symptoms until it's already severe. Most people with consistently high readings report feeling completely normal.
Symptoms like headache, dizziness, or nosebleeds are not reliable indicators of blood pressure status at mild-to-moderate elevations. Overt symptoms are more consistently associated with a hypertensive crisis — readings at or above 180/120 mmHg — not with the more common stage 1 or stage 2 elevations that still carry long-term cardiovascular risk.
What this means in practice: a cuff reading, not how you feel, is the only way to know where your blood pressure actually sits. Feeling “fine” is not evidence of a normal result, and it isn't evidence of an abnormal one either — it simply isn't the right kind of evidence for this question.
Myth: Everyone Needs the Same Blood Pressure Target
This is also false, and the disagreement between guideline bodies isn't a sign the science is unsettled — it reflects that different patient groups carry different risk profiles, and that targets get revised as new trial evidence comes in.
The 2017 American College of Cardiology/American Heart Association guideline set a goal of under 130/80 mmHg for most adults, including older adults and people with chronic kidney disease or diabetes, based substantially on findings from the Systolic Blood Pressure Intervention Trial (SPRINT). That same guideline explicitly carves out an exception: for older adults with multiple chronic conditions or limited life expectancy, it recommends an individualized goal set with a clinician, not a fixed number.
Other guideline bodies, including for the same patient groups, have landed in different places at different times:
- The American College of Physicians and American Academy of Family Physicians have recommended a less aggressive systolic target for older adults — under 150, or under 140 with a history of stroke or high cardiovascular risk.
- The American Diabetes Association held its general target at under 140/90 in its 2018 Standards of Care, with a lower 130/80 goal reserved for patients individually assessed as higher-risk. By its 2023 Standards, the ADA moved its general target for people with diabetes to under 130/80, aligning more closely with the ACC/AHA number as more trial evidence accumulated.
- Kidney-disease-specific and international guideline bodies have set their own separate thresholds, some less strict than the U.S. cardiology guideline, particularly for older patients.
The common thread: age, kidney function, diabetes status, frailty, and overall cardiovascular risk all change where a target should sit, and the numbers get revised over time within the same organization as evidence changes. A single fixed number that ignores those factors isn't more rigorous — it's just incomplete, and possibly outdated.
What This Page Can and Can't Settle
This page can tell you that “feeling fine” isn't diagnostic, and that “everyone should hit X number” oversimplifies a genuinely guideline-dependent, evolving question. What it can't do is tell you what your own target should be. That depends on factors — your age, kidney function, other conditions, and how your numbers were measured — that only show up in an actual reading and a conversation with whoever manages your care.
That conversation matters even more if a medication change is already on the table. If you're also evaluating or taking a GLP-1 medication, for example, blood pressure monitoring takes on added importance: GLP-1 therapy has its own additive blood-pressure-lowering effect on top of existing antihypertensives, which is covered in more detail in our GLP-1 safety guide for cardiac patients.
If a reading has come back elevated, or a prior medication discussion referenced a specific target number, the more useful next step is asking directly which guideline that number is based on, and whether it accounts for your specific risk factors and how recently it was updated. That's a more productive question than searching for one universal cutoff, because the evidence above shows one doesn't exist in the way the myth assumes.
The Bottom Line
Blood pressure is measured, not felt, and the “normal” target is a range that shifts with who you are and when the guideline was last revised — not a fixed line everyone is measured against. Both facts are more useful for an actual medication conversation than either myth they're correcting.